Compare Amgen, Inc. (AMGN) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Rush Street Interactive Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Rush Street Interactive Inc trades at $33.25 (market cap $3.44B). The key difference: Amgen, Inc. is far larger — about 57× Rush Street Interactive Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Rush Street Interactive Inc pays none. Which is the better fit depends on your goals.
| AMGN | RSI | |
|---|---|---|
Market Cap | $196.12B | $3.44B |
Sector | Health | Technology |
52-Week High | $388.16 | $33.40 |
52-Week Low | $271.18 | $14.51 |
Enterprise Value | $241.41B | $3.11B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
RSI stock trades at $33.40, up 2.36% today, with strong technical momentum and a bullish moving average signal. The company reported Q1 2026 EPS of $0.14, beating expectations, with revenue growth projected to $1.2B in 2026. Positive sentiment is driven by a 76.9% analyst buy rating and a $100M share repurchase program announced on May 5, 2026.
Outlook remains positive given earnings beats and growth initiatives, but high P/E of 98.24 signals valuation risk. Key risks include competitive pressures and reliance on sports betting trends. The consensus price target is $29.44, suggesting limited upside from current levels amid elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
